Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report

ABSTRACT:

Background

The resistance mechanisms to osimertinib encompass on-target molecular alterations, such as the well-known epidermal growth factor receptor (EGFR) C797S resistance mutation, and off-target molecular alterations, such as the high-frequency MET amplification, but there’s no further clear-cut therapeutic option to date for these individuals yet. Here we reported a lung adenocarcinoma (LUAD) patient who progressed on osimertinib benefited from multiline combination target-therapy and obtained a long-term progression-free survival (PFS).

Case Description

A 70-year-old Chinese woman without a smoking history presented with stage IV advanced LUAD harboring EGFR 19del and then developed EGFR T790M mutation after 6-month treatment of gefitinib [a first-generation EGFR t

SUBMITTER:  

PROVIDER: S-EPMC9552262 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature